| |OCTOBER 20248NIH TRIAL FINDS MPOX VACCINE SAFE & EFFECTIVE IN ADOLESCENTSSANOFI & ORANO PARTNER TO ADVANCE NEXT-GEN RADIOLIGAND MEDICINESNational Institutes of Health (NIH) showed that an mpox vaccine administered to teenagers was safe and produced the same level of antibody response as in adults. Young people are one of the demographics impacted by mpox in the ongoing Clade I mpox epidemic.The interim findings of this clinical study were shared at the IDWeek2024 event in Los Angeles. The initial human instance of mpox was documented in 1970 in the Democratic Republic of the Congo (DRC). There have been two varieties of the virus responsible for mpox that have been recognized. Clade I is native to Central Africa and has the potential to result in serious sickness. Clade II, which is exclusive to West Africa, sparked the worldwide mpox pandemic that started in 2022 and often leads to less severe sickness. Individuals with weakened immune systems, children, and pregnant individuals are particularly susceptible to severe mpox regardless of the virus clade.Many adolescents and children are being impacted in the ongoing Clade I outbreak in the DRC and other African nations. The MVA-BN vaccine is authorized in multiple countries for preventing mpox and smallpox in adults, but limited evidence exists for approval in individuals under 18 years old. POSanofi & Orano Med, which is a part of the Orano Group and specializes in targeted alphatherapies for cancer treatment, have agreed to collaborate in order to advance the development of advanced radioligand treatments for rare cancers.Sanofi and Orano will collaborate with Orano Med to create a new entity dedicated to developing next-generation radioligand therapies using lead-212 alpha-emitting isotopes, utilizing their expertise and radioligand pipeline. This deal comes after Sanofi's announcement of a sole licensing agreement with Orano Med and RadioMedix to progress radioligand therapies (RLTs) in rare cancers, specifically targeting the late-stage project, AlphaMedix.Paul Hudson, CEO, Sanofi, said: "We are excited to partner with Orano in establishing a French pioneer that unites our respective expertise in biopharma and nuclear technology to drive groundbreaking progress in the fight against cancer. As a French biopharmaceutical company, we are deeply committed to fostering and enabling innovation in our home country. This collaboration is part of a broader effort to strengthen our ties within the scientific community, both in France and globally, with the goal of advancing the development of cutting-edge treatments for patients."Nicolas Maes, CEO, Orano Group, said: "The success of Orano Med is an example of our group's ability to diversify beyond our core nuclear business. By applying our expertise in nuclear materials to fields like targeted alpha therapies, we are demonstrating that nuclear technology can have a positive societal impact, not just for energy and climate, but also for human health. This innovation reflects Orano's commitment to exploring new opportunities and taking bold steps to address some of the world's most pressing challenges." POTOP STORIES
< Page 7 | Page 9 >